Cellular heterogeneity and molecular evolution in cancer.

Intratumor heterogeneity represents a major obstacle to effective cancer treatment and personalized medicine. However, investigators are now elucidating intratumor heterogeneity at the single-cell level due to improvements in technologies. Better understanding of the composition of tumors, and monitoring changes in cell populations during disease progression and treatment, will improve cancer diagnosis and therapeutic design. Measurements of intratumor heterogeneity may also be used as biomarkers to predict the risk of progression and therapeutic resistance. We summarize important considerations related to intratumor heterogeneity during tumor evolution. We also discuss experimental approaches that are commonly used to infer intratumor heterogeneity and describe how these methodologies can be translated into clinical practice.

[1]  J. Salk.  Clonal evolution in cancer , 2010 .

[2]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[3]  A. Oudenaarden,et al.  Single-molecule transcript counting of stem-cell markers in the mouse intestine , 2011, Nature Cell Biology.

[4]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[5]  H. Dressman,et al.  Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Gnant,et al.  Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. , 2003, Endocrine-related cancer.

[7]  D. Kerr,et al.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.

[8]  D. Larsimont,et al.  Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Zoltan Szallasi,et al.  Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.

[10]  Satoshi Ikeda,et al.  Detection of gene point mutation in paraffin sections using in situ loop‐mediated isothermal amplification , 2007, Pathology international.

[11]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[12]  M. Esteller,et al.  Aberrant epigenetic landscape in cancer: how cellular identity goes awry. , 2010, Developmental cell.

[13]  J. Andersen,et al.  Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. , 1996, Cancer research.

[14]  M. Clarke,et al.  Cancer stem cells: models and concepts. , 2007, Annual review of medicine.

[15]  A. Oudenaarden,et al.  Validating transcripts with probes and imaging technology , 2011, Nature Methods.

[16]  M. Stratton,et al.  Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing , 2008, Proceedings of the National Academy of Sciences.

[17]  Z. Szallasi,et al.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.

[18]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[19]  Rebecca A Betensky,et al.  Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.

[20]  A. Vincent-Salomon,et al.  Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Stephanie Alexander,et al.  Cancer Invasion and the Microenvironment: Plasticity and Reciprocity , 2011, Cell.

[22]  O. Nordgård,et al.  Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy , 2011, International Journal of Colorectal Disease.

[23]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[24]  A. Heguy,et al.  PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression , 2011, Breast Cancer Research and Treatment.

[25]  Carissa A. Sanchez,et al.  Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.

[26]  C. Sigman,et al.  Cancer biomarkers: selecting the right drug for the right patient , 2012, Nature Reviews Drug Discovery.

[27]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[28]  Ming Chen,et al.  Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens , 2011, Cell Biochemistry and Biophysics.

[29]  Kikuya Kato,et al.  Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib , 2008, Cancer science.

[30]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[31]  J. Hicks,et al.  Insight into the heterogeneity of breast cancer through next-generation sequencing. , 2011, The Journal of clinical investigation.

[32]  James R. Downing,et al.  Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells , 2011, Nature.

[33]  Ian Tomlinson,et al.  Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog , 1999, Nature medicine.

[34]  M. Gönen,et al.  Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. , 2010, The Journal of clinical investigation.

[35]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[36]  M. Papotti,et al.  Mixed medullary-follicular thyroid carcinoma. Molecular evidence for a dual origin of tumor components. , 1999, The American journal of pathology.

[37]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Raymond R Tubbs,et al.  Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. , 2009, Archives of pathology & laboratory medicine.

[39]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[40]  G. Heppner,et al.  Tumor heterogeneity: biological implications and therapeutic consequences , 2004, Cancer and Metastasis Reviews.

[41]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[42]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[43]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[44]  D. Ledbetter,et al.  Multicolor Spectral Karyotyping of Human Chromosomes , 1996, Science.

[45]  Igor Jurisica,et al.  Gene Expression Profiling in Cervical Cancer: An Exploration of Intratumor Heterogeneity , 2006, Clinical Cancer Research.

[46]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[47]  K. Odunsi,et al.  Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer , 2008, Clinical Cancer Research.

[48]  Paul Marjoram,et al.  Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers , 2009, Proceedings of the National Academy of Sciences.

[49]  D. Wodarz,et al.  Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy. , 2003, Cancer research.

[50]  Michael C. Montalto,et al.  Autofocus methods of whole slide imaging systems and the introduction of a second-generation independent dual sensor scanning method , 2011, Journal of pathology informatics.

[51]  Hong Wu,et al.  A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. , 2010, Cancer research.

[52]  R. DePinho,et al.  Telomeres and telomerase in cancer. , 2010, Carcinogenesis.

[53]  A. Ashworth,et al.  Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.

[54]  James R. Downing,et al.  Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.

[55]  H. Hemmi,et al.  A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer , 2001, British Journal of Cancer.

[56]  L. Loeb,et al.  Cancer cells exhibit a mutator phenotype. , 1998, Advances in cancer research.

[57]  Michael R. Speicher,et al.  High resolution array-CGH analysis of single cells , 2006, Nucleic acids research.

[58]  Yudi Pawitan,et al.  Improved Grading of Breast Adenocarcinomas Based on Genomic Instability , 2004, Cancer Research.

[59]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[60]  Lani F. Wu,et al.  Cellular Heterogeneity: Do Differences Make a Difference? , 2010, Cell.

[61]  K. Schaefer,et al.  Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases , 2010, Clinical Cancer Research.

[62]  David G. Mutch,et al.  Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing , 2009, Nucleic acids research.

[63]  D. Carrasco,et al.  PIK3CA mutations in in situ and invasive breast carcinomas. , 2010, Cancer research.

[64]  S. Makino.  FURTHER EVIDENCE FAVORING THE CONCEPT OF THE STEM CELL IN ASCITES TUMORS OF RATS , 1955, Annals of the New York Academy of Sciences.

[65]  M. Maio,et al.  Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine , 2004, Cancer Research.

[66]  Debyani Chakravarty,et al.  Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.

[67]  A. Oudenaarden,et al.  Nature, Nurture, or Chance: Stochastic Gene Expression and Its Consequences , 2008, Cell.

[68]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[69]  A. Børresen-Dale,et al.  Paired distribution of molecular subtypes in bilateral breast carcinomas. , 2011, Cancer genetics.

[70]  E. Fee,et al.  Rudolf Carl Virchow: medical scientist, social reformer, role model. , 2006, American journal of public health.

[71]  K. Polyak.  Going small is the new big , 2010, Nature Methods.

[72]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[73]  Richard R McKay,et al.  The accuracy of dynamic predictive autofocusing for whole slide imaging , 2011, Journal of pathology informatics.

[74]  E. Davila,et al.  The Clinical Importance of the Heterogeneity of HER2 neu , 2010, Case Reports in Oncology.

[75]  P. Workman,et al.  Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. , 2012, Annual review of pharmacology and toxicology.

[76]  Huanming Yang,et al.  Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor , 2012, Cell.

[77]  M. Werner,et al.  Interphase cytogenetics in pathology: principles, methods, and applications of fluorescence in situ hybridization (FISH) , 1997, Histochemistry and Cell Biology.

[78]  S. Aebi,et al.  The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. , 1998, British Journal of Cancer.

[79]  J. Dick,et al.  Stem cell concepts renew cancer research. , 2008, Blood.

[80]  J. Shipley,et al.  Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays , 2008, Nature Protocols.

[81]  D. M. Walker,et al.  In Situ Detection of Specific p53 Mutations in Cultured Cells Using the Amplification Refractory Mutation System Polymerase Chain Reaction , 2000, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[82]  O. Bagasra.  Protocols for the in situ PCR-amplification and detection of mRNA and DNA sequences , 2007, Nature Protocols.

[83]  I. Ellis,et al.  The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast , 2006, Journal of Clinical Pathology.

[84]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[85]  L. Jin,et al.  In situ hybridization: Methods and applications , 1997, Journal of clinical laboratory analysis.

[86]  Franziska Michor,et al.  Intratumor Heterogeneity in Evolutionary Models of Tumor Progression , 2011, Genetics.

[87]  Matthew B. Wilson,et al.  Tumor Suppressor p16INK4A Regulates Polycomb-mediated DNA Hypermethylation in Human Mammary Epithelial Cells* , 2006, Journal of Biological Chemistry.

[88]  I. Burney.  Cancer Chemotherapy and Biotherapy : Principles and Practice , 2011 .

[89]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[90]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[91]  M. Tsuboi,et al.  Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib , 2006, Clinical Cancer Research.

[92]  J. Troge,et al.  Inferring tumor progression from genomic heterogeneity. , 2010, Genome research.

[93]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[94]  Charles Swanton,et al.  Breast cancer genome heterogeneity: a challenge to personalised medicine? , 2011, Breast Cancer Research.

[95]  David J. Harrison,et al.  Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence , 2011, Journal of visualized experiments : JoVE.

[96]  Claude Preudhomme,et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.

[97]  Huanming Yang,et al.  Single-Cell Exome Sequencing and Monoclonal Evolution of a JAK2-Negative Myeloproliferative Neoplasm , 2012, Cell.

[98]  N. Fedoroff,et al.  Mutations, epimutations, and the developmental programming of the maize Suppressor‐mutator transposable element , 1989, BioEssays : news and reviews in molecular, cellular and developmental biology.

[99]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[100]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[101]  S. Leibler,et al.  Bacterial Persistence as a Phenotypic Switch , 2004, Science.

[102]  A. Forrest,et al.  Oestrogen receptors and breast cancer: Current status , 1980, The British journal of surgery.

[103]  Alexander van Oudenaarden,et al.  Variability in gene expression underlies incomplete penetrance , 2009, Nature.

[104]  Jannik N. Andersen,et al.  Cancer genomics: from discovery science to personalized medicine , 2011, Nature Medicine.

[105]  H. Höfler,et al.  Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. , 1999, Cancer genetics and cytogenetics.

[106]  Juri G. Gelovani,et al.  Methodological and practical challenges for personalized cancer therapies , 2011, Nature Reviews Clinical Oncology.

[107]  L. Coussens,et al.  Tumor stroma and regulation of cancer development. , 2006, Annual review of pathology.

[108]  P. Komminoth,et al.  Comparison of indirect and direct in-situ polymerase chain reaction in cell preparations and tissue sections , 1993, Histochemistry.

[109]  Kevin A. Janes,et al.  Identifying single-cell molecular programs by stochastic profiling , 2010, Nature Methods.

[110]  M. Monden,et al.  Gene expression of colorectal cancer: preoperative genetic diagnosis using endoscopic biopsies. , 2008, International journal of oncology.

[111]  K. Kinzler,et al.  Carcinogen-specific induction of genetic instability , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[112]  R. DePinho,et al.  Connecting chromosomes, crisis, and cancer. , 2002, Science.

[113]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[114]  Hannah H. Chang,et al.  Transcriptome-wide noise controls lineage choice in mammalian progenitor cells , 2008, Nature.

[115]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[116]  S. Lindquist,et al.  Protein homeostasis and the phenotypic manifestation of genetic diversity: principles and mechanisms. , 2010, Annual review of genetics.

[117]  Stephen Yip,et al.  MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance , 2009, Clinical Cancer Research.

[118]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[119]  N. Carter,et al.  Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.

[120]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[121]  Charlotte Kuperwasser,et al.  Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy , 2008, Breast Cancer Research.

[122]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[123]  Hannah H. Chang,et al.  Non-genetic heterogeneity — a mutation-independent driving force for the somatic evolution of tumours , 2009, Nature Reviews Genetics.

[124]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[125]  C Lengauer,et al.  Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.

[126]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[127]  R. Kerbel,et al.  Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development , 2004, Clinical Cancer Research.

[128]  C. Sawyers,et al.  Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia , 2002, Current opinion in hematology.

[129]  I. Fidler,et al.  Tumor heterogeneity and the biology of cancer invasion and metastasis. , 1978, Cancer research.

[130]  D. Dexter,et al.  Heterogeneity of tumor cells from a single mouse mammary tumor. , 1978, Cancer research.

[131]  Pradeep S Rajendran,et al.  Single-cell dissection of transcriptional heterogeneity in human colon tumors , 2011, Nature Biotechnology.

[132]  I. Fidler,et al.  Metastasis results from preexisting variant cells within a malignant tumor. , 1977, Science.

[133]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[134]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[135]  J. D. de Visser,et al.  Clonal Interference and the Periodic Selection of New Beneficial Mutations in Escherichia coli , 2006, Genetics.

[136]  J. Sørensen,et al.  Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer , 2012, Cancer Chemotherapy and Pharmacology.

[137]  Patrik Edén,et al.  Intratumor versus intertumor heterogeneity in gene expression profiles of soft‐tissue sarcomas , 2005, Genes, chromosomes & cancer.

[138]  K. Polyak,et al.  The microenvironment in breast cancer progression: biology and implications for treatment , 2011, Breast Cancer Research.

[139]  K. Anderson,et al.  Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.

[140]  M. Gerlinger,et al.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine , 2010, British Journal of Cancer.

[141]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[142]  J. Feldman,et al.  Marked Intratumoral Heterogeneity of the Proto‐Oncogene Her‐2/neu Determined by Three Different Detection Systems , 1999, The breast journal.

[143]  Dimitris Visvikis,et al.  Impact of Tumor Size and Tracer Uptake Heterogeneity in 18F-FDG PET and CT Non–Small Cell Lung Cancer Tumor Delineation , 2011, The Journal of Nuclear Medicine.

[144]  R. Milo,et al.  Dynamic Proteomics of Individual Cancer Cells in Response to a Drug , 2008, Science.

[145]  C. Preudhomme,et al.  A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. , 2003, The New England journal of medicine.

[146]  D. Sidransky,et al.  Rates of p16 (MTS1) mutations in primary tumors with 9p loss. , 1994, Science.

[147]  C. Maley,et al.  The role of genetic diversity in cancer. , 2010, The Journal of clinical investigation.

[148]  Eunyoung Kang,et al.  Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance , 2012, Modern Pathology.

[149]  M. Mazumdar,et al.  Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma , 2012, PloS one.

[150]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[151]  K. Allison,et al.  Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity. , 2011, American journal of clinical pathology.

[152]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[153]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.